Literature DB >> 19219778

Fatal pulmonary embolism following hip and knee replacement. A study of 2153 cases using routine mechanical prophylaxis and selective chemoprophylaxis.

A Shepherd1, C Mills.   

Abstract

In order to prevent fatal pulmonary embolism, TED stockings, foot pumps and early mobilisation on the second post-operative day are used at our centre. Only patients deemed to be high risk (previous DVT/PE or obese) are given clexane as inpatients and warfarin for six weeks post-op. From the hospital database 1137 primary total hip replacements and 1017 primary total knee re-placements were identified and the figures were confirmed with the theatre implant order books. The cause of death for those patients on the database, now deceased, was obtained from the coroner. Where a postmortem had not been performed the patient was assumed to have died of a PE. Within three months of surgery, a fatal PE rate of 0.09% (95% CI 0.00-0.26%) following hip replacement and 0.20% (95% CI 0.00-0.46%) after knee replacement was found. Thirty-four patients had been discharged on warfarin according to the pharmacy records. We would therefore not recommend the routine use of chemical thromboprophylaxis following joint replacement.

Entities:  

Year:  2006        PMID: 19219778     DOI: 10.5301/hip.2008.4713

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  3 in total

1.  Risk Factor Analysis for 30-Day Mortality After Primary THA in a Single Institution.

Authors:  Fernando Comba; Ignacio Alonso Hidalgo; Martín Buttaro; Francisco Piccaluga
Journal:  HSS J       Date:  2012-06-30

2.  Spinal subdural hematoma with cauda equina syndrome: A complication of combined spinal epidural anesthesia.

Authors:  Neha Singhal; Priyanka Sethi; Jitesh Kumar Jain; Saurabh Agarwal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Apr-Jun

Review 3.  Factors predicting venous thromboembolism after spine surgery.

Authors:  Tao Wang; Si-Dong Yang; Wen-Zheng Huang; Feng-Yu Liu; Hui Wang; Wen-Yuan Ding
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.